GORE VIABAHN® Versus Plain Old Balloon Angioplasty (POBA) for Superficial Femoral Artery (SFA) In-Stent Restenosis

General Inclusion Criteria: * Patient presenting with lifestyle-limiting claudication, rest pain or minor tissue loss (Rutherford classification from 2 to 5) * Patient is willing to comply with specified follow-up evaluations at the specified times * Patient is \>18 years old * Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study * Patient has a projected life-expectancy of at least 24 months * Noninvasive lower extremity arterial studies (resting or exercise) demonstrate ankle-brachial index ≤0.8 * Patient is eligible for treatment with the Viabahn® Endoprosthesis (W.L. Gore) * Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure Angiographic Inclusion Criteria * Restenotic or reoccluded lesion located in a stent which was previously implanted (\>30 days) in the superficial femoral artery, suitable for endovascular therapy * Total target lesion length between 4 and 27 cm (comprising in-stent restenosis and adjacent stenotic disease) * Minimum of 1.0cm of healthy vessel (non-stenotic) both proximal and distal to the treatment area * Popliteal artery is patent at the intercondylar fossa of the femur to P3 * Target vessel diameter visually estimated to be \>4mm and \<7.6 mm at the proximal and distal treatment segments within the SFA * Guidewire and delivery system successfully traversed lesion * There is angiographic evidence of at least one-vessel-runoff to the foot, that does not require intervention (\<50% stenotic) Exclusion criteria : * Untreated flow-limiting aortoiliac stenotic disease * Presence of a chronic total occlusion, i.e. a complete occlusion of the failed bare stent that cannot be re-opened with thrombolysis or does not allow easy passage of the guidewire by the physician * Any previous surgery in the target vessel * Severe ipsilateral common/deep femoral disease requiring surgical reintervention * Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment * Femoral or popliteal aneurysm located at the target vessel * Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis) * No patent tibial arteries (\>50% stenosis) * Prior ipsilateral femoral artery bypass * Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc) or other medical condition that would preclude compliance with the study protocol or 2-year life expectancy * Serum creatinine \>2.5mg/dL within 45 days prior to study procedure unless the subject is currently on dialysis * Major distal amputation (above the transmetatarsal) in the study or non-study limb * Septicemia or bacteremia * Any previously known coagulation disorder, including hypercoagulability * Contraindication to anticoagulation or antiplatelet therapy * Known allergies to stent or stent graft components (nickel-titanium or ePTFE) * Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure * Patient with known hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II * Currently participating in another clinical research trial, unless approved by W.L. Gore \& Associates in advance of study enrolment * Angiographic evidence of intra-arterial thrombus or atheroembolism from inflow treatment * Any planned surgical intervention/procedure within 30 days of the study procedure * Target lesion access not performed by transfemoral approach.